Oncotarget, Aiding In The Advancement of The Oncology Scientific Community

Oncotarget, the most significant peer-reviewed oncology research-based publication had recently published a cover story which uncovered a new technique that can successfully be used to treat a particularly aggressive type of breast cancer. This publishing revealed that the specific molecules that could treat this ailment might soon be used to formulate a treatment plan. Hormone therapy based treatments can aid in the efforts of medical professionals that are trying to target specific cancer cells that metastasize to other organs. Watch this video on Youtube.


This detailed research paper published by Oncotarget revealed that estrogen-based hormone therapy when tested on mouse test subjects resulted in some cases of remission as well as few cases of preventing further growth of malignant tumors. These findings will be tested on a few more test subjects before they will be finally considered for a clinical trial.

Since Oncotarget has been established, this publication does its fair share to assist the advancement of the science community as well as encourage budding oncology researchers. Recently, Oncotarget awarded grants to enable four researchers to attend the Frontiers in Cancer Science 2017 conference that was held in November 2017. This conference was held at a venue in Singapore, and the travel grants ensured that the chosen researchers could discuss cancer discoveries made by the oncology sector in the recent past.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget


The four researchers who were given the travel sponsorship were Mohd Anas Shami from India, Rajni Kumari from India, Ruhi Sandeep from India and Vladan Milosevic from Italy. These science researchers have created papers on topics such as anti-renal cancer medicines, metastatic genes, using Cyclin F as a novel regulator of Glioma Epigenetics and chemoresistant tendencies in cancer stem cells.


The conference that was held in the first week of November was the result of seven significant cancer institutes getting together and hosting this event. Oncotarget selected the four researchers for the travel sponsorships based on their academic merits and accuracy of the published work done by these four-brilliant people. Oncotarget was proud to have given these four researchers the means to attend this crucial conference and be a part of the scientific community that is steadily creating more effective treatments for various types of cancers. Learn more about Oncotarget at Eurekalert.org.